For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
This article from The Motley Fool compares two healthcare-focused ETFs: the iShares Global Healthcare ETF (IXJ) and the VanEck Pharmaceutical ETF (PPH). IXJ offers broad global exposure across 110 stocks including medical device and biotech firms, with an expense ratio of 0.4% and a 1.50% yield. PPH is more concentrated, holding 26 pharmaceutical giants, with a 0.4% expense ratio and a 2.0% yield. Performance data shows PPH outperforming IXJ year-to-date (7% vs 2%), over 3 years (13.8% vs 6.6%), and over 5 years (10.5% vs 4.9%), though IXJ edges ahead over 10 years (8.49% vs 8.46%). PPH has slightly higher risk due to concentration. The article concludes that PPH is the better pharmaceutical ETF to buy in 2026, favoring its focused approach and higher returns.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection